VivoSeq
Gastroenterology

Exocrine Pancreatic Insufficiency

3

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Exocrine Pancreatic Insufficiency is an early-stage landscape with 3 programs across 4 companies. The most active players are Anagram Therapeutics, Inc., AbbVie, Axcan Pharma.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Anagram Therapeutics, Inc.

2 programs

Phase 2AbbVie logo

AbbVie

1 program

Phase 2A

Axcan Pharma

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 23

ANG003 Dose a

Anagram Therapeutics, Inc.

ANG003 Dose B

Anagram Therapeutics, Inc.

Creon

AbbVie

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

8

clinical trials

Completed4 · 50%
Recruiting4 · 50%

Clinical Trials

Trial Activity

8 trials

THE MALABSORPTION BLOOD TEST TRIAL WILL HELP DETERMINE THE BENEFITS OF PANCREATIC ENZYME REPLACEMENT THERAPY IN PATIENTS WITH MILD TO MODERATE EXOCRINE PANCREATIC INSUFFICIENCY.
Recruiting·—·Phase 4·NCT07418593·80 enrolled
Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease
Recruiting·HHospices Civils de Lyon·N/A·NCT03915262·50 enrolled
A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Recruiting·AAnagram Therapeutics, Inc.·Phase 2·NCT07450547·113 enrolled
An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants
Recruiting·MMayo Clinic·Approved·NCT07285863·24 enrolled
An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI)
Completed·AAxcan Pharma·Phase 2·NCT00559052·22 enrolled
A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 1·NCT00676702·13 enrolled
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Completed·AbbVie logoAbbVie·N/A·NCT04949828·63 enrolled
Development of a Registry of Patients With Pancreatic Exocrine Insufficiency of Different Etiologies: EURO-PEI Registry
Completed·HHospital Clinico Universitario de Santiago·N/A·NCT05450627·1,015 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)